Recently, catheter-based procedures have been developed to repair the tricuspid valve or reduce the leak without open surgery ...

A fully automated deep learning workflow for echocardiography in pulmonary arterial hypertension (PAH) is accurate and feasible.

PARIS — By assessing residual regurgitation after a transcatheter tricuspid valve repair with a four-grade rather than three-grade system, physicians can predict survival more accurately, reported ...

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication for ...

Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65–85 living with moderate or greater valvular heart disease (VHD) in the United States, and at ...

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In ...

One-year follow-up data suggest that a novel transcatheter tricuspid valve replacement (TTVR) device may provide another potential alternative to surgery for patients with severe tricuspid ...

Heart valves allow blood to flow one way and prevent it from flowing in the wrong direction. The tricuspid valve controls blood flow between the right atrium and right ventricle. The bicuspid or ...

Edwards Lifesciences has received US Food and Drug Administration (FDA) approval for its Evoque tricuspid valve replacement system, which becomes the first transcatheter therapy to be approved in the ...